Zimmer Biomet Holdings, Inc. (NYSE:ZBH) - Equities researchers at Leerink Swann cut their Q3 2017 earnings per share estimates for Zimmer Biomet Holdings in a research note issued to investors on Thursday. Leerink Swann analyst R. Newitter now anticipates that the medical equipment provider will post earnings per share of $1.76 for the quarter, down from their previous estimate of $1.98. Leerink Swann currently has a “Outperform” rating and a $146.00 target price on the stock. Leerink Swann also issued estimates for Zimmer Biomet Holdings’ Q4 2017 earnings at $2.27 EPS, FY2017 earnings at $8.24 EPS, FY2018 earnings at $8.83 EPS and FY2019 earnings at $9.60 EPS.
Zimmer Biomet Holdings (NYSE:ZBH) last issued its earnings results on Thursday, July 27th. The medical equipment provider reported $2.08 earnings per share for the quarter, missing the Zacks’ consensus estimate of $2.10 by $0.02. Zimmer Biomet Holdings had a return on equity of 16.70% and a net margin of 9.12%. The business had revenue of $1.95 billion during the quarter, compared to analysts’ expectations of $1.95 billion. During the same period last year, the firm posted $2.02 EPS. Zimmer Biomet Holdings’s quarterly revenue was up 1.1% compared to the same quarter last year.
COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The legal version of this piece of content can be read at https://stocknewstimes.com/2017/07/31/q3-2017-eps-estimates-for-zimmer-biomet-holdings-inc-zbh-lowered-by-analyst.html.
A number of other equities research analysts also recently commented on the company. Needham & Company LLC lifted their target price on Zimmer Biomet Holdings from $151.00 to $153.00 and gave the stock a “strong-buy” rating in a report on Friday, April 28th. Oppenheimer Holdings, Inc. set a $132.00 target price on Zimmer Biomet Holdings and gave the stock a “buy” rating in a report on Friday, April 28th. Zacks Investment Research downgraded Zimmer Biomet Holdings from a “hold” rating to a “sell” rating in a report on Tuesday, April 4th. Goldman Sachs Group, Inc. (The) initiated coverage on Zimmer Biomet Holdings in a report on Tuesday, May 16th. They set a “sell” rating and a $92.00 target price for the company. Finally, Wells Fargo & Company downgraded Zimmer Biomet Holdings from an “outperform” rating to a “market perform” rating in a report on Friday, April 28th. Three research analysts have rated the stock with a sell rating, eight have given a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $137.76.
Zimmer Biomet Holdings (NYSE:ZBH) opened at 123.78 on Monday. Zimmer Biomet Holdings has a 12 month low of $95.63 and a 12 month high of $133.49. The firm has a 50-day moving average price of $127.89 and a 200-day moving average price of $121.20. The stock has a market cap of $24.98 billion, a price-to-earnings ratio of 35.25 and a beta of 1.21.
The firm also recently disclosed a quarterly dividend, which was paid on Friday, July 28th. Stockholders of record on Friday, June 23rd were given a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.78%. The ex-dividend date of this dividend was Wednesday, June 21st. Zimmer Biomet Holdings’s dividend payout ratio (DPR) is presently 27.59%.
In other news, VP Chad F. Phipps sold 6,200 shares of Zimmer Biomet Holdings stock in a transaction that occurred on Friday, May 5th. The stock was sold at an average price of $116.76, for a total value of $723,912.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Sang Yi sold 17,731 shares of Zimmer Biomet Holdings stock in a transaction that occurred on Monday, June 12th. The stock was sold at an average price of $124.56, for a total value of $2,208,573.36. The disclosure for this sale can be found here. 1.07% of the stock is owned by insiders.
Hedge funds have recently modified their holdings of the company. Parkside Financial Bank & Trust raised its stake in shares of Zimmer Biomet Holdings by 2.7% in the first quarter. Parkside Financial Bank & Trust now owns 839 shares of the medical equipment provider’s stock worth $102,000 after buying an additional 22 shares in the last quarter. Parallel Advisors LLC raised its stake in shares of Zimmer Biomet Holdings by 20.8% in the first quarter. Parallel Advisors LLC now owns 1,157 shares of the medical equipment provider’s stock worth $138,000 after buying an additional 199 shares in the last quarter. IHT Wealth Management LLC raised its stake in shares of Zimmer Biomet Holdings by 28.4% in the first quarter. IHT Wealth Management LLC now owns 1,158 shares of the medical equipment provider’s stock worth $139,000 after buying an additional 256 shares in the last quarter. Sandy Spring Bank raised its stake in shares of Zimmer Biomet Holdings by 1.7% in the first quarter. Sandy Spring Bank now owns 1,222 shares of the medical equipment provider’s stock worth $149,000 after buying an additional 20 shares in the last quarter. Finally, Penserra Capital Management LLC raised its stake in shares of Zimmer Biomet Holdings by 9.5% in the first quarter. Penserra Capital Management LLC now owns 1,288 shares of the medical equipment provider’s stock worth $157,000 after buying an additional 112 shares in the last quarter. 84.37% of the stock is currently owned by hedge funds and other institutional investors.
Zimmer Biomet Holdings Company Profile
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
